Myriad Genetics, Inc. (NASDAQ:MYGN)’s shares decreased 9.22% to $34.27. The company on Mar. 3 announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, demonstrating that 65 percent of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test. Prolaris is a 46-gene molecular diagnostic test that has been evaluated in 11 clinical studies with more than 5,000 patients. Myriad Genetics, Inc. (NASDAQ:MYGN) stock opened at $34.65 in last session, and closed at $34.60, while the day range of MYGN stock is $32.76-$35.74. The stock showed a neagtive weekly performance of -7.49%.
Goldman Sachs began coverage on shares of Canadian Solar (NASDAQ:CSIQ) in a report issued on Friday, AnalystRatings.NETreports. The firm issued a neutral rating on the stock. Canadian Solar Inc. (NASDAQ:CSIQ) stock opened at $36.00, in last session and closed at $34.23, by loosed -5.02%. The 52 week range was $3.12-$44.50. Company’s market capitalization is $1.84 billion.
In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh downgraded the rating on XOMA Corp (NASDAQ:XOMA) from Buy to Hold, and lowered the price target from $8.00 to $7.00. XOMA Corp (NASDAQ:XOMA) stock loosed -8.71% and finished the last session at $5.87. The EPS of the stock remained -1.38. Company’s market capitalization is $618.62 million.
Vringo, Inc. (Nasdaq: VRNG) announced operating results for the year ended December 31, 2013. Vringo also released a new investor presentation, which is available online at http://bit.ly/1oFniVe. Vringo, Inc. (NASDAQ:VRNG) stock opened the session at $3.85, and closed the session at $3.66. The 52 week range of the VRNG stock remained $2.61-$5.45 and the day range was $3.48-$3.85.
Leave a Reply